Bjerrum Andreas, Lindebjerg Jan, Andersen Ole, Fischer Anders, Lynge Elsebeth
Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
Department of Pathology, Vejle Hospital, Vejle, Denmark.
Int J Cancer. 2020 Aug 15;147(4):940-947. doi: 10.1002/ijc.32850. Epub 2020 Jan 25.
Fecal occult blood test (FOBT) screening for colorectal cancer (CRC) is implemented in several countries. Approximately half of all FOBT-positive persons have screen-detected adenomas. Despite removal of these, patients with large/multiple adenomas have increased risk of later developing new advanced adenomas and CRC. International guidelines exist for colonoscopic surveillance following adenoma removal. These divide patients into low-, intermediate- and high-risk groups. We followed 711 FOBT-positive patients with screening adenoma identified during population-based CRC screening in two Danish counties in 2005-2006. As reference population, we included 1,240,348 persons in the same age group from the rest of Denmark not included in the screening. We estimated the long-term CRC risk stratified by adenoma findings during screening and compared to the reference group. After 12 years follow-up, the CRC incidence among all adenoma patients was 322 cases per 100,000 person-years (95% confidence interval [CI]: 212-489) ranging from 251 (95% CI: 94-671) to 542 (95% CI: 300-978) cases per 100,000 person-years in the low- and high-risk groups, respectively. In the reference population, the CRC incidence was 244 (95% CI: 242-247) per 100,000. Patients with screen-detected high-risk adenomas after a positive FOBT had an almost doubled risk of CRC compared to the reference population (adjusted hazard ratio [aHR] 1.95, 95% CI: 1.08-3.51), and the incidence in those with no follow-up visits was over 3.6 (aHR 3.64, 95% CI: 1.82-7.29) times the incidence in the reference population. The increased CRC risk could be controlled if high-risk patients underwent follow-up colonoscopy (aHR 0.87, 95% CI: 0.28-2.69).
多个国家实施了粪便潜血试验(FOBT)筛查结直肠癌(CRC)。所有FOBT阳性者中约有一半通过筛查发现患有腺瘤。尽管切除了这些腺瘤,但患有大腺瘤/多发性腺瘤的患者日后发生新的高级别腺瘤和CRC的风险会增加。对于腺瘤切除后的结肠镜监测,国际上有相关指南。这些指南将患者分为低风险、中风险和高风险组。我们对2005 - 2006年在丹麦两个县基于人群的CRC筛查中发现的711例FOBT阳性且患有筛查腺瘤的患者进行了随访。作为对照人群,我们纳入了丹麦其他地区同年龄组的1,240,348人,这些人未纳入筛查。我们根据筛查时腺瘤的发现情况对长期CRC风险进行分层,并与对照人群进行比较。经过12年的随访,所有腺瘤患者的CRC发病率为每100,000人年322例(95%置信区间[CI]:212 - 489),低风险组和高风险组分别为每100,000人年251例(95% CI:94 - 671)和542例(95% CI:300 - 978)。在对照人群中,CRC发病率为每100,000人年244例(95% CI:242 - 247)。与对照人群相比,FOBT阳性后通过筛查发现患有高风险腺瘤的患者患CRC的风险几乎增加了一倍(调整后风险比[aHR] 1.95,95% CI:1.08 - 3.51),且未进行随访的患者发病率是对照人群发病率的3.6倍多(aHR 3.64,95% CI:1.82 - 7.29)。如果高风险患者接受随访结肠镜检查,CRC风险增加的情况可以得到控制(aHR 0.87,95% CI:0.28 - 2.69)。